Table 2. Description of the study sample according to whether or not they have HyFoSy tubal patency (2 groups) No tubal patency = Bilateral tubal occlusion (n=5) + Unilateral tubal occlusion (n=15) Tubal patency = No tubal blockade (n=59)
Tubal patency HyFoSy
No (n=20) Yes (n=59) p-value
N % N %
Age (years), Mean (SD) 34.0 (4.1) - 33 (3.4) - 0.319*
BMI (kg/m2), Mean (SD) 25.7 (4.4) - 25.1 (5.1) - 0.688*
Smoker
No
Yes
Ex-Smoker
13
5
2
65.0
25.0
10.0
46
9
3
79.3
15.5
5.2
0.429**
IgG Chlamydia
Negative
Positive
15
5
75.0
25.0
53
6
89.8
10.2
0.098**
VAS HyFoSy intraprocedural, Mean (SD) 5.4 (2.9) - 5.2 (2.2) - 0.791***
VAS HyFoSy post-procedural, Mean (SD) 3.1 (2.7) - 2.4 (2.4) - 0.280***
Endometriosis
No
Yes
18
2
90
10
58
1
98.3
1.7
0.156****
Infertility time (months)1, Mean (SD) 26.6 (15.5) - 26.3 (15.9) - 0.784***
AMH (ng/mL)
< 0,6
0.6 - 1.1
> 1.1
0
1
18
0.0
5.3
94.7
3
5
50
5.2
8.6
86.2
0.520**
Ovarian pathology
No
Yes2
18
2
90.0
10.0
56
3
94.9
5.1
0.596****
Pelvic inflammatory disease history
No
Yes
19
1
95.0
5.0
59
0
100
0.0
0.253****
Antral follicle count
< 10
10 - 20
> 20
1
7
12
5.0
35.0
60.0
9
21
29
15.3
35.6
49.2
0.453**
Soldo Programme
No
Yes
4
16
20.0
80.0
20
39
33.9
66.1
0.277****

AMH: anti-Müllerian hormone, BMI: body mass index, SD: Standard Deviation, VAS: visual analogue scale.
1 Only for patients who do not belong to the SOLDO programme.
2 Type of ovarian pathology: Without tubal patency: Endometrioma (2); With bilateral tubal patency: Endometrioma (1) and Cyst (2).
T test / **χ2 test / ***Mann-Whitney test / ****Fisher’s exact test
Soldo: Soldo in Catalonia: Access to ART for women without a male partner